Editas Medicine, Inc. (0IFK.L)
USD 1.02
(0.22%)
USD 1.02
(0.22%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 78.12 Million USD | 296.32% |
| 2022 | 19.71 Million USD | -22.83% |
| 2021 | 25.54 Million USD | -71.85% |
| 2020 | 90.73 Million USD | 341.93% |
| 2019 | 20.53 Million USD | -35.71% |
| 2018 | 31.93 Million USD | 132.64% |
| 2017 | 13.72 Million USD | 126.8% |
| 2016 | 6.05 Million USD | 271.58% |
| 2015 | 1.62 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.13 Million USD | -98.11% |
| 2024 Q2 | 513 Thousand USD | -54.8% |
| 2024 Q3 | 61 Thousand USD | -88.11% |
| 2023 Q4 | 60.04 Million USD | 1025.36% |
| 2023 FY | 78.12 Million USD | 296.32% |
| 2023 Q1 | 9.85 Million USD | 50.72% |
| 2023 Q2 | 2.88 Million USD | -70.69% |
| 2023 Q3 | 5.33 Million USD | 84.83% |
| 2022 Q2 | 6.36 Million USD | -6.04% |
| 2022 FY | 19.71 Million USD | -22.83% |
| 2022 Q1 | 6.77 Million USD | -45.7% |
| 2022 Q4 | 6.53 Million USD | 15461.9% |
| 2022 Q3 | 42 Thousand USD | -99.34% |
| 2021 Q4 | 12.46 Million USD | 101.21% |
| 2021 Q1 | 6.49 Million USD | -43.09% |
| 2021 Q2 | 379 Thousand USD | -94.17% |
| 2021 Q3 | 6.19 Million USD | 1535.09% |
| 2021 FY | 25.54 Million USD | -71.85% |
| 2020 Q1 | 5.72 Million USD | -53.41% |
| 2020 FY | 90.73 Million USD | 341.93% |
| 2020 Q4 | 11.41 Million USD | -81.83% |
| 2020 Q3 | 62.84 Million USD | 484.62% |
| 2020 Q2 | 10.74 Million USD | 87.82% |
| 2019 Q3 | 3.84 Million USD | 65.15% |
| 2019 FY | 20.53 Million USD | -35.71% |
| 2019 Q4 | 12.28 Million USD | 219.23% |
| 2019 Q2 | 2.33 Million USD | 12.61% |
| 2019 Q1 | 2.06 Million USD | -66.19% |
| 2018 Q3 | 14.51 Million USD | 96.95% |
| 2018 Q4 | 6.11 Million USD | -57.86% |
| 2018 FY | 31.93 Million USD | 132.64% |
| 2018 Q1 | 3.92 Million USD | 7.09% |
| 2018 Q2 | 7.37 Million USD | 87.73% |
| 2017 FY | 13.72 Million USD | 126.8% |
| 2017 Q1 | 682 Thousand USD | -24.05% |
| 2017 Q2 | 3.09 Million USD | 354.11% |
| 2017 Q3 | 6.28 Million USD | 102.84% |
| 2017 Q4 | 3.66 Million USD | -41.63% |
| 2016 Q4 | 898 Thousand USD | -6.65% |
| 2016 FY | 6.05 Million USD | 271.58% |
| 2016 Q3 | 962 Thousand USD | -71.61% |
| 2016 Q2 | 3.38 Million USD | 320.87% |
| 2016 Q1 | 805 Thousand USD | 1.64% |
| 2015 Q2 | 167 Thousand USD | 0.0% |
| 2015 Q3 | 670 Thousand USD | 301.2% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | 792 Thousand USD | 18.21% |
| 2015 FY | 1.62 Million USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -393.107% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -191.254% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 80.438% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -811.268% |
| bluebird bio, Inc. | 29.49 Million USD | -164.851% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -272.582% |
| Imunon, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.479% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 97.938% |
| Myriad Genetics, Inc. | 678.4 Million USD | 88.484% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 95.86% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 87.141% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.947% |
| Waters Corporation | 2.95 Billion USD | 97.358% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.818% |
| Biogen Inc. | 9.83 Billion USD | 99.206% |
| Nektar Therapeutics | 90.12 Million USD | 13.314% |
| Perrigo Company plc | 4.65 Billion USD | 98.322% |
| Dynavax Technologies Corporation | 232.28 Million USD | 66.367% |
| Illumina, Inc. | 4.5 Billion USD | 98.265% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -6470.479% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 38.507% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 96.771% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 55.67% |
| Evolus, Inc. | 202.08 Million USD | 61.342% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -150.002% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.404% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 32.846% |
| FibroGen, Inc. | 147.75 Million USD | 47.126% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 98.857% |
| OPKO Health, Inc. | 863.49 Million USD | 90.953% |
| Homology Medicines, Inc. | -6.65 Million USD | 1274.605% |
| Geron Corporation | 237 Thousand USD | -32863.291% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 95.727% |
| Exelixis, Inc. | 1.83 Billion USD | 95.731% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -115.363% |
| Zoetis Inc. | 8.54 Billion USD | 99.086% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 71.13% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -2132.086% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.208% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 90.081% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 93.717% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 83.805% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 90.579% |
| Blueprint Medicines Corporation | 249.38 Million USD | 68.673% |
| Insmed Incorporated | 305.2 Million USD | 74.403% |
| TG Therapeutics, Inc. | 233.66 Million USD | 66.566% |
| Incyte Corporation | 3.69 Billion USD | 97.886% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 92.555% |